{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:20:52Z","timestamp":1787656852964,"version":"build-2736575974"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12607-y","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:40:45Z","timestamp":1787654445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular cartography of breast cancer: decoding genomes, heterogeneity and the tumor microenvironment for personalized targeted therapeutics"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-6834","authenticated-orcid":false,"given":"Ashik Anil","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7283-1597","authenticated-orcid":false,"given":"Kannan","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9006-0567","authenticated-orcid":false,"given":"Diya","family":"Gibu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. P.","family":"Muhammed Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5228-148X","authenticated-orcid":false,"given":"S.","family":"Aravind Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0832-1586","authenticated-orcid":false,"given":"Nijin Samuel","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9560-8489","authenticated-orcid":false,"given":"H. C.","family":"Ujwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"12607_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V et al (2025) Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 31:1154\u20131162. https:\/\/doi.org\/10.1038\/s41591-025-03502-3","journal-title":"Nat Med"},{"key":"12607_CR2","doi-asserted-by":"publisher","first-page":"14438","DOI":"10.3390\/cimb46120866","volume":"46","author":"F Fanfarillo","year":"2024","unstructured":"Fanfarillo F, Caronti B, Lucarelli M et al (2024) Alcohol consumption and breast and ovarian cancer development: molecular pathways and mechanisms. Curr Issues Mol Biol 46:14438\u201314452. https:\/\/doi.org\/10.3390\/cimb46120866","journal-title":"Curr Issues Mol Biol"},{"key":"12607_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-3-031-75907-9_3","volume-title":"Clinical ophthalmic oncology","author":"BT Hill","year":"2025","unstructured":"Hill BT, Shah H, Winter A (2025) Etiology of cancer. In: Singh AD, Damato BE (eds) Clinical ophthalmic oncology. Springer Nature Switzerland, Cham, pp 17\u201322. https:\/\/doi.org\/10.1007\/978-3-031-75907-9_3"},{"key":"12607_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010039","volume":"17","author":"RM Ple\u0219ea","year":"2024","unstructured":"Ple\u0219ea RM, Riza A-L, Ahmet AM et al (2024) Clinically significant BRCA1 and BRCA2 germline variants in breast cancer\u2014a single-center experience. Cancers 17:39. https:\/\/doi.org\/10.3390\/cancers17010039","journal-title":"Cancers"},{"key":"12607_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03553-9","volume":"22","author":"M Pal","year":"2024","unstructured":"Pal M, Das D, Pandey M (2024) Understanding genetic variations associated with familial breast cancer. World J Surg Oncol 22:271. https:\/\/doi.org\/10.1186\/s12957-024-03553-9","journal-title":"World J Surg Oncol"},{"key":"12607_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00363-1","volume":"12","author":"L Guo","year":"2023","unstructured":"Guo L, Kong D, Liu J et al (2023) Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol 12:3. https:\/\/doi.org\/10.1186\/s40164-022-00363-1","journal-title":"Exp Hematol Oncol"},{"key":"12607_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041320","volume":"15","author":"B Kinnel","year":"2023","unstructured":"Kinnel B, Singh SK, Oprea-Ilies G, Singh R (2023) Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers (Basel) 15:1320. https:\/\/doi.org\/10.3390\/cancers15041320","journal-title":"Cancers (Basel)"},{"key":"12607_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859581","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Tian Q, Gao H et al (2022) Immunity and extracellular matrix characteristics of breast cancer subtypes based on identification by T helper cells profiling. Front Immunol 13:859581. https:\/\/doi.org\/10.3389\/fimmu.2022.859581","journal-title":"Front Immunol"},{"key":"12607_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CMAR.S316700","volume":"14","author":"Y Fan","year":"2022","unstructured":"Fan Y, He S (2022) The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag Res 14:1\u201317. https:\/\/doi.org\/10.2147\/CMAR.S316700","journal-title":"Cancer Manag Res"},{"key":"12607_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2159-8290.CD-24-1662","volume":"15","author":"JJ Brzezinski","year":"2025","unstructured":"Brzezinski JJ, Malkin D (2025) Knudson\u2019s \u201ctwo-hit\u201d hypothesis and cancer predisposition: a bit more complicated but still going strong. Cancer Discov 15:258\u2013260. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1662","journal-title":"Cancer Discov"},{"key":"12607_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41421-023-00614-3","volume":"9","author":"C Chen","year":"2023","unstructured":"Chen C, Lin C-J, Pei Y-C et al (2023) Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell Discov 9:125. https:\/\/doi.org\/10.1038\/s41421-023-00614-3","journal-title":"Cell Discov"},{"key":"12607_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jnci\/djac196","volume":"115","author":"BWX Lim","year":"2023","unstructured":"Lim BWX, Li N, Mahale S et al (2023) Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants. JNCI J Natl Cancer Inst 115:181\u2013189. https:\/\/doi.org\/10.1093\/jnci\/djac196","journal-title":"JNCI J Natl Cancer Inst"},{"key":"12607_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/his.14808","volume":"82","author":"A Sokolova","year":"2023","unstructured":"Sokolova A, Johnstone KJ, McCart Reed AE, Simpson PT, Lakhani SR (2023) Hereditary breast cancer: syndromes, tumour pathology and molecular testing. Histopathology 82:70\u201382. https:\/\/doi.org\/10.1111\/his.14808","journal-title":"Histopathology"},{"key":"12607_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00669-9","volume":"10","author":"J-Y Kim","year":"2024","unstructured":"Kim J-Y, Park K, Park W-Y et al (2024) Prognostic value of structural variants in early breast cancer patients. NPJ Breast Cancer 10:64. https:\/\/doi.org\/10.1038\/s41523-024-00669-9","journal-title":"NPJ Breast Cancer"},{"key":"12607_CR15","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.3390\/cancers14215278","volume":"14","author":"C McCarthy-Leo","year":"2022","unstructured":"McCarthy-Leo C, Darwiche F, Tainsky MA (2022) DNA repair mechanisms, protein interactions and therapeutic targeting of the MRN complex. Cancers 14:5278. https:\/\/doi.org\/10.3390\/cancers14215278","journal-title":"Cancers"},{"key":"12607_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcaa022","volume":"2","author":"R Dueva","year":"2020","unstructured":"Dueva R, Iliakis G (2020) Replication protein A: a multifunctional protein with roles in DNA replication, repair and beyond. NAR Cancer 2:zcaa022. https:\/\/doi.org\/10.1093\/narcan\/zcaa022","journal-title":"NAR Cancer"},{"key":"12607_CR17","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","volume":"82","author":"TK Foo","year":"2022","unstructured":"Foo TK, Xia B (2022) BRCA1-dependent and independent recruitment of PALB2\u2013BRCA2\u2013RAD51 in the DNA damage response and cancer. Cancer Res 82:3191\u20133197. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1535","journal-title":"Cancer Res"},{"key":"12607_CR18","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2020.3","volume":"22","author":"HL Smith","year":"2020","unstructured":"Smith HL, Southgate H, Tweddle DA, Curtin NJ (2020) DNA damage checkpoint kinases in cancer. Expert Rev Mol Med 22:e2. https:\/\/doi.org\/10.1017\/erm.2020.3","journal-title":"Expert Rev Mol Med"},{"key":"12607_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00018-019-03365-1","volume":"77","author":"Y Sun","year":"2020","unstructured":"Sun Y, McCorvie TJ, Yates LA, Zhang X (2020) Structural basis of homologous recombination. Cell Mol Life Sci 77:3\u201318. https:\/\/doi.org\/10.1007\/s00018-019-03365-1","journal-title":"Cell Mol Life Sci"},{"key":"12607_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-022-00447-3","volume":"17","author":"J Kim","year":"2023","unstructured":"Kim J, Jeong K, Jun H et al (2023) Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1\/2 mutations. Hum Genomics 17:2. https:\/\/doi.org\/10.1186\/s40246-022-00447-3","journal-title":"Hum Genomics"},{"key":"12607_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417488","volume":"24","author":"E Manousakis","year":"2023","unstructured":"Manousakis E, Miralles CM, Esquerda MG, Wright RHG (2023) CDKN1A\/p21 in breast cancer: part of the problem, or part of the solution? Int J Mol Sci 24:17488. https:\/\/doi.org\/10.3390\/ijms242417488","journal-title":"Int J Mol Sci"},{"key":"12607_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","volume":"9","author":"DS Peiffer","year":"2023","unstructured":"Peiffer DS, Zhao F, Chen N et al (2023) Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol 9:500. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7476","journal-title":"JAMA Oncol"},{"key":"12607_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.894861","volume":"12","author":"X Liu","year":"2022","unstructured":"Liu X, Fang Y, Li Y, Li Y, Qi L, Wang X (2022) Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials. Front Oncol 12:894861. https:\/\/doi.org\/10.3389\/fonc.2022.894861","journal-title":"Front Oncol"},{"key":"12607_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100772","volume":"8","author":"E De Azambuja","year":"2023","unstructured":"De Azambuja E, Agostinetto E, Procter M et al (2023) Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open 8:100772. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100772","journal-title":"ESMO Open"},{"key":"12607_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","volume":"80","author":"SE Nunnery","year":"2020","unstructured":"Nunnery SE, Mayer IA (2020) Targeting the PI3K\/AKT\/mTOR pathway in hormone-positive breast cancer. Drugs 80:1685\u20131697. https:\/\/doi.org\/10.1007\/s40265-020-01394-w","journal-title":"Drugs"},{"key":"12607_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-024-02136-y","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA (2025) Inavolisib: First approval. Drugs 85:271\u2013278. https:\/\/doi.org\/10.1007\/s40265-024-02136-y","journal-title":"Drugs"},{"key":"12607_CR27","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.2174\/0109298673365863250101070254","volume":"32","author":"J Zhang","year":"2025","unstructured":"Zhang J (2025) FDA approves inavolisib combo for PIK3CA-mutated, HR+ BreastCancer. Curr Med Chem 32:6409\u20136411. https:\/\/doi.org\/10.2174\/0109298673365863250101070254","journal-title":"Curr Med Chem"},{"key":"12607_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-026-00850-9","author":"F Rojo","year":"2026","unstructured":"Rojo F, Guarneri V, Fusco N et al (2026) Standardized analytical verification of ctDNA ESR1 mutation testing in metastatic HR+\/HER2\u2212 breast cancer: a European multicentre study using dPCR and NGS-based liquid biopsy. Mol Diagn Ther. https:\/\/doi.org\/10.1007\/s40291-026-00850-9","journal-title":"Mol Diagn Ther"},{"key":"12607_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00783-2","volume":"11","author":"J Fuentes-Antr\u00e1s","year":"2025","unstructured":"Fuentes-Antr\u00e1s J, Elliott MJ, Main SC et al (2025) Personalized ctDNA monitoring in metastatic HR+\/HER2\u2212 breast cancer patients during endocrine and CDK4\/6 inhibitor therapy. NPJ Breast Cancer 11:74. https:\/\/doi.org\/10.1038\/s41523-025-00783-2","journal-title":"NPJ Breast Cancer"},{"key":"12607_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-73126-9","volume":"17","author":"MJ Elliott","year":"2026","unstructured":"Elliott MJ, Fuentes-Antr\u00e1s J, Main SC et al (2026) Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4\/6 inhibitor therapy. Nat Commun 17:7183. https:\/\/doi.org\/10.1038\/s41467-026-73126-9","journal-title":"Nat Commun"},{"key":"12607_CR31","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1186\/s12885-025-14599-7","volume":"25","author":"K Egebjerg","year":"2025","unstructured":"Egebjerg K, Spanggaard I, Ahlborn LB et al (2025) Mutational landscape assessed in tumor tissue and circulating tumor DNA during treatment of patients with HER2\/ERBB2-mutated solid tumors. BMC Cancer 25:1272. https:\/\/doi.org\/10.1186\/s12885-025-14599-7","journal-title":"BMC Cancer"},{"key":"12607_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","volume":"34","author":"K Jhaveri","year":"2023","unstructured":"Jhaveri K, Eli LD, Wildiers H et al (2023) Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 34:885\u2013898. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.003","journal-title":"Ann Oncol"},{"key":"12607_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215456","volume":"14","author":"X Sun","year":"2022","unstructured":"Sun X, Liu K, Lu S, He W, Du Z (2022) Targeted therapy and immunotherapy for heterogeneous breast cancer. Cancers (Basel) 14:5456. https:\/\/doi.org\/10.3390\/cancers14215456","journal-title":"Cancers (Basel)"},{"key":"12607_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4274\/ejbh.galenos.2021.2021-4-3","volume":"17","author":"H Zhu","year":"2021","unstructured":"Zhu H, Do\u011fan BE (2021) American Joint Committee on Cancer\u2019s Staging System for Breast Cancer, Eighth Edition: summary for clinicians. Eur J Breast Health 17:234\u2013238. https:\/\/doi.org\/10.4274\/ejbh.galenos.2021.2021-4-3","journal-title":"Eur J Breast Health"},{"key":"12607_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00428-018-2301-9","volume":"472","author":"G Cserni","year":"2018","unstructured":"Cserni G, Chmielik E, Cserni B, Tot T (2018) The new TNM-based staging of breast cancer. Virchows Arch 472:697\u2013703. https:\/\/doi.org\/10.1007\/s00428-018-2301-9","journal-title":"Virchows Arch"},{"key":"12607_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11091555","volume":"11","author":"C Fumagalli","year":"2021","unstructured":"Fumagalli C, Barberis M (2021) Breast cancer heterogeneity. Diagnostics (Basel) 11:1555. https:\/\/doi.org\/10.3390\/diagnostics11091555","journal-title":"Diagnostics (Basel)"},{"key":"12607_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch Pathol Lab Med 144:545\u2013563. https:\/\/doi.org\/10.5858\/arpa.2019-0904-SA","journal-title":"Arch Pathol Lab Med"},{"key":"12607_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.20.25223","volume":"217","author":"DC Teichgraeber","year":"2021","unstructured":"Teichgraeber DC, Guirguis MS, Whitman GJ (2021) Breast cancer staging: updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. AJR Am J Roentgenol 217:278\u2013290. https:\/\/doi.org\/10.2214\/AJR.20.25223","journal-title":"AJR Am J Roentgenol"},{"key":"12607_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-022-06839-2","volume":"198","author":"CMS Hassing","year":"2023","unstructured":"Hassing CMS, Mejdahl MK, L\u00e6nkholm A-V, Kroman N, Knoop AS, Tvedskov THF (2023) Adjuvant chemotherapy in patients with ER-negative\/HER2-negative, T1abN0 breast cancer: a nationwide study. Breast Cancer Res Treat 198:103\u2013112. https:\/\/doi.org\/10.1007\/s10549-022-06839-2","journal-title":"Breast Cancer Res Treat"},{"key":"12607_CR40","doi-asserted-by":"publisher","DOI":"10.4137\/CPath.S31563","volume":"8","author":"J Makki","year":"2015","unstructured":"Makki J (2015) Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol 8:CPath.S31563. https:\/\/doi.org\/10.4137\/CPath.S31563","journal-title":"Clin Med Insights Pathol"},{"key":"12607_CR41","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.6026\/9732063002002069","volume":"20","author":"R Waykar","year":"2024","unstructured":"Waykar R, Kumarapillai S (2024) Breast cancer histopathology, classification and clinical management: current perspectives. Bioinformation 20:2069\u20132079. https:\/\/doi.org\/10.6026\/9732063002002069. (Department of Pharmacy, Lincoln University College, Wisma Lincoln, Jalan SS 6\/12, 47301 Petaling Jaya, Selangor Darul Ehsan, Malaysia)","journal-title":"Bioinformation"},{"key":"12607_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/his.14786","volume":"82","author":"EA Rakha","year":"2023","unstructured":"Rakha EA, Tse GM, Quinn CM (2023) An update on the pathological classification of breast cancer. Histopathology 82:5\u201316. https:\/\/doi.org\/10.1111\/his.14786","journal-title":"Histopathology"},{"key":"12607_CR43","doi-asserted-by":"publisher","unstructured":"Inflammatory breast cancer biomarkers and biology (2024). In: International Review of Cell and Molecular Biology. Elsevier. https:\/\/doi.org\/10.1016\/bs.ircmb.2023.11.002","DOI":"10.1016\/bs.ircmb.2023.11.002"},{"key":"12607_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02019-4","volume":"27","author":"JS Kim","year":"2025","unstructured":"Kim JS, Lee JH, Yeon Y, An D, Kim SJ, Noh M-G, Lee S (2025) Predicting Nottingham grade in breast cancer digital pathology using a foundation model. Breast Cancer Res 27:58. https:\/\/doi.org\/10.1186\/s13058-025-02019-4","journal-title":"Breast Cancer Res"},{"key":"12607_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-025-07718-2","volume":"212","author":"AJAD Freitas","year":"2025","unstructured":"Freitas AJAD, Causin RL, Calfa S et al (2025) Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes. Breast Cancer Res Treat 212:237\u2013250. https:\/\/doi.org\/10.1007\/s10549-025-07718-2","journal-title":"Breast Cancer Res Treat"},{"key":"12607_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10549-022-06530-6","volume":"192","author":"TTA Nguyen","year":"2022","unstructured":"Nguyen TTA, Postlewait LM, Zhang C et al (2022) Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. Breast Cancer Res Treat 192:509\u2013516. https:\/\/doi.org\/10.1007\/s10549-022-06530-6","journal-title":"Breast Cancer Res Treat"},{"key":"12607_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T et al (2024) Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35:159\u2013182. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"},{"key":"12607_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, Van Der Noordaa M et al (2022) Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23:149\u2013160. https:\/\/doi.org\/10.1016\/S1470-2045(21)00589-1","journal-title":"Lancet Oncol"},{"key":"12607_CR49","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R et al (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 391:1981\u20131991. https:\/\/doi.org\/10.1056\/NEJMoa2409932","journal-title":"N Engl J Med"},{"key":"12607_CR50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/his.15346","volume":"86","author":"E Yang","year":"2025","unstructured":"Yang E, D\u2019Alfonso TM, Morrow M, Brogi E, Wen HY (2025) Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical\u2013pathological correlation. Histopathology 86:441\u2013449. https:\/\/doi.org\/10.1111\/his.15346","journal-title":"Histopathology"},{"key":"12607_CR51","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"key":"12607_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02001-0","volume":"27","author":"H Lv","year":"2025","unstructured":"Lv H, Yue J, Zhang Q et al (2025) Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China. Breast Cancer Res 27:45. https:\/\/doi.org\/10.1186\/s13058-025-02001-0","journal-title":"Breast Cancer Res"},{"key":"12607_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im S-A et al (2025) Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol 43:285\u2013296. https:\/\/doi.org\/10.1200\/JCO.24.00920","journal-title":"J Clin Oncol"},{"key":"12607_CR54","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"12607_CR55","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S et al (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:514\u2013524. https:\/\/doi.org\/10.1056\/NEJMoa1911149","journal-title":"N Engl J Med"},{"key":"12607_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jamaoncol.2023.6038","volume":"10","author":"CX Ma","year":"2024","unstructured":"Ma CX, Suman VJ, Sanati S et al (2024) Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor\u2013Rich\/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: a phase 3 randomized clinical trial. JAMA Oncol 10:362. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6038","journal-title":"JAMA Oncol"},{"key":"12607_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14737140.2024.2330601","volume":"24","author":"A Stravodimou","year":"2024","unstructured":"Stravodimou A, Voutsadakis IA (2024) Neo-adjuvant therapies for ER positive\/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond. Expert Rev Anticancer Ther 24:117\u2013135. https:\/\/doi.org\/10.1080\/14737140.2024.2330601","journal-title":"Expert Rev Anticancer Ther"},{"key":"12607_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235499","volume":"15","author":"MJ Bravo","year":"2023","unstructured":"Bravo MJ, Burgos-Molina AM, Garc\u00eda-Aranda M, Redondo M, T\u00e9llez T (2023) Unlocking new avenues in breast cancer treatment: the synergy of kinase inhibitors and immunotherapy. Cancers 15:5499. https:\/\/doi.org\/10.3390\/cancers15235499","journal-title":"Cancers"},{"key":"12607_CR59","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N Engl J Med 384:2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"12607_CR60","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"12607_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01849-y","volume":"39","author":"R Gupta","year":"2022","unstructured":"Gupta R, Gupta S, Antonios B et al (2022) Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Med Oncol 39:258. https:\/\/doi.org\/10.1007\/s12032-022-01849-y","journal-title":"Med Oncol"},{"key":"12607_CR62","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","volume":"24","author":"M Stanowicka-Grada","year":"2023","unstructured":"Stanowicka-Grada M, Senkus E (2023) Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Curr Treat Options Oncol 24:1633\u20131650. https:\/\/doi.org\/10.1007\/s11864-023-01137-5","journal-title":"Curr Treat Options Oncol"},{"key":"12607_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1073797","volume":"9","author":"J Hunia","year":"2022","unstructured":"Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, Nowis D (2022) The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. Front Mol Biosci 9:1073797. https:\/\/doi.org\/10.3389\/fmolb.2022.1073797","journal-title":"Front Mol Biosci"},{"key":"12607_CR64","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/j.ijrobp.2024.01.096","volume":"118","author":"P Oppelt","year":"2024","unstructured":"Oppelt P, Ley J, Liu J, Adkins D (2024) Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): a single-Arm, phase 2 trial. Int J Radiat Oncol 118:e42\u2013e43. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.096","journal-title":"Int J Radiat Oncol"},{"key":"12607_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102569","volume":"14","author":"B Smolarz","year":"2022","unstructured":"Smolarz B, Nowak AZ, Romanowicz H (2022) Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel) 14:2569. https:\/\/doi.org\/10.3390\/cancers14102569","journal-title":"Cancers (Basel)"},{"key":"12607_CR66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/oncologie-2022-1011","volume":"25","author":"XJ Tan","year":"2023","unstructured":"Tan XJ, Cheor WL, Cheng EM, Ab Rahman KS, Wan Muhamad WZA, Leow WZ (2023) Breast cancer status, grading system, etiology, and challenges in Asia: an updated review. Oncologie 25:99\u2013110. https:\/\/doi.org\/10.1515\/oncologie-2022-1011","journal-title":"Oncologie"},{"key":"12607_CR67","first-page":"171","volume":"104","author":"KP Trayes","year":"2021","unstructured":"Trayes KP, Cokenakes SEH (2021) Breast cancer treatment. Am Fam Physician 104:171\u2013178","journal-title":"Am Fam Physician"},{"key":"12607_CR68","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-023-07212-7","volume":"204","author":"K Altundag","year":"2024","unstructured":"Altundag K (2024) The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ. Breast Cancer Res Treat 204:189\u2013190. https:\/\/doi.org\/10.1007\/s10549-023-07212-7","journal-title":"Breast Cancer Res Treat"},{"key":"12607_CR69","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/0115665240349468241113065031","volume":"25","author":"AE Gallas","year":"2025","unstructured":"Gallas AE, Morenikeji GO, King RE, Adegbaju MS, Ayoola A, Taiwo G, Morenikeji OB (2025) An overview of invasive ductal carcinoma (IDC) in women\u2019s breast cancer. Curr Mol Med 25:361\u2013371. https:\/\/doi.org\/10.2174\/0115665240349468241113065031","journal-title":"Curr Mol Med"},{"key":"12607_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1785","volume":"4","author":"J Zhang","year":"2021","unstructured":"Zhang J, Lu C-Y, Chen H-M, Wu S-Y (2021) Neoadjuvant chemotherapy or endocrine therapy for invasive ductal carcinoma of the breast with high hormone receptor positivity and human epidermal growth factor receptor 2 negativity. JAMA Netw Open 4:e211785. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.1785","journal-title":"JAMA Netw Open"},{"key":"12607_CR71","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/cncr.35125","volume":"130","author":"S \u00d6ztekin","year":"2024","unstructured":"\u00d6ztekin S, Hooning MJ, Van Deurzen CHM et al (2024) The effect of (neo)adjuvant chemotherapy on long\u2010term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: a retrospective cohort study. Cancer 130:927\u2013935. https:\/\/doi.org\/10.1002\/cncr.35125","journal-title":"Cancer"},{"key":"12607_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00594-3","volume":"9","author":"H Record","year":"2023","unstructured":"Record H, Clelland E, Rothschild HT et al (2023) Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer. NPJ Breast Cancer 9:88. https:\/\/doi.org\/10.1038\/s41523-023-00594-3","journal-title":"NPJ Breast Cancer"},{"key":"12607_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05790-874","author":"F Bertucci","year":"2024","unstructured":"Bertucci F, Guille A, Lerebours F et al (2024) Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy. J Transl Med. https:\/\/doi.org\/10.1186\/s12967-024-05790-874","journal-title":"J Transl Med"},{"key":"12607_CR74","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jss.2023.08.047","volume":"293","author":"H-Y Lai","year":"2024","unstructured":"Lai H-Y, Loh E-W, Su C-M, Chiang M-H, Tam K-W (2024) Outcomes of breast-conserving therapy in patients with inflammatory breast cancer: a meta-analysis. J Surg Res 293:458\u2013467. https:\/\/doi.org\/10.1016\/j.jss.2023.08.047","journal-title":"J Surg Res"},{"key":"12607_CR75","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.7150\/ijbs.108803","volume":"21","author":"F Li","year":"2025","unstructured":"Li F, Gao C, Huang Y, Qiao Y, Xu H, Liu S, Wu H (2025) Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategies. Int J Biol Sci 21:2606\u20132628. https:\/\/doi.org\/10.7150\/ijbs.108803","journal-title":"Int J Biol Sci"},{"key":"12607_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115432","volume":"44","author":"EJ Kay","year":"2025","unstructured":"Kay EJ, Zanivan S (2025) The tumor microenvironment is an ecosystem sustained by metabolic interactions. Cell Rep 44:115432. https:\/\/doi.org\/10.1016\/j.celrep.2025.115432","journal-title":"Cell Rep"},{"key":"12607_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061899","volume":"15","author":"K Wright","year":"2023","unstructured":"Wright K, Ly T, Kriet M, Czirok A, Thomas SM (2023) Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers 15:1899. https:\/\/doi.org\/10.3390\/cancers15061899","journal-title":"Cancers"},{"key":"12607_CR78","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cac2.12291","volume":"42","author":"D Hu","year":"2022","unstructured":"Hu D, Li Z, Zheng B et al (2022) Cancer\u2010associated fibroblasts in breast cancer: challenges and opportunities. Cancer Commun 42:401\u2013434. https:\/\/doi.org\/10.1002\/cac2.12291","journal-title":"Cancer Commun"},{"key":"12607_CR79","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.9973","author":"F Wang","year":"2019","unstructured":"Wang F, Sun W, Zhang J, Fan Y (2019) Cancer\u2011associated fibroblast regulation of tumor neo\u2011angiogenesis as a therapeutic target in cancer (review). Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2019.9973","journal-title":"Oncol Lett"},{"key":"12607_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8:198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1","journal-title":"Signal Transduct Target Ther"},{"key":"12607_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1403122","volume":"12","author":"AN Kazakova","year":"2024","unstructured":"Kazakova AN, Lukina MM, Anufrieva KS et al (2024) Exploring the diversity of cancer-associated fibroblasts: insights into mechanisms of drug resistance. Front Cell Dev Biol 12:1403122. https:\/\/doi.org\/10.3389\/fcell.2024.1403122","journal-title":"Front Cell Dev Biol"},{"key":"12607_CR82","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1172\/JCI137552","volume":"130","author":"EC De Heer","year":"2020","unstructured":"De Heer EC, Jalving M, Harris AL (2020) HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest 130:5074\u20135087. https:\/\/doi.org\/10.1172\/JCI137552","journal-title":"J Clin Invest"},{"key":"12607_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1064661","author":"S Luo","year":"2022","unstructured":"Luo S, Jiang Y, Zheng A et al (2022) Targeting hypoxia-inducible factors for breast cancer therapy: a narrative review. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.1064661","journal-title":"Front Pharmacol"},{"key":"12607_CR84","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/1947601911432334","volume":"2","author":"S Ziyad","year":"2011","unstructured":"Ziyad S, Iruela-Arispe ML (2011) Molecular mechanisms of tumor angiogenesis. Genes Cancer 2:1085\u20131096. https:\/\/doi.org\/10.1177\/1947601911432334","journal-title":"Genes Cancer"},{"key":"12607_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838133","volume":"13","author":"NM Ayoub","year":"2022","unstructured":"Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE (2022) Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches. Front Pharmacol 13:838133. https:\/\/doi.org\/10.3389\/fphar.2022.838133","journal-title":"Front Pharmacol"},{"key":"12607_CR86","doi-asserted-by":"publisher","first-page":"1560393","DOI":"10.3389\/fimmu.2025.1560393","volume":"16","author":"H Jin","year":"2025","unstructured":"Jin H, Meng X, Feng J (2025) Mechanisms of tumor-associated macrophages in breast cancer and treatment strategy. Front Immunol 16:1560393. https:\/\/doi.org\/10.3389\/fimmu.2025.1560393","journal-title":"Front Immunol"},{"key":"12607_CR87","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.20141836","volume":"212","author":"T Kitamura","year":"2015","unstructured":"Kitamura T, Qian B-Z, Soong D et al (2015) CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med 212:1043\u20131059. https:\/\/doi.org\/10.1084\/jem.20141836","journal-title":"J Exp Med"},{"key":"12607_CR88","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L (2025) Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res 44:145. https:\/\/doi.org\/10.1186\/s13046-025-03377-9","journal-title":"J Exp Clin Cancer Res"},{"key":"12607_CR89","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2147\/OTT.S168317","volume":"11","author":"Y Chen","year":"2018","unstructured":"Chen Y, Tan W, Wang C (2018) Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelia l&;mesenchymal transition. OncoTargets Ther 11:3817\u20133826. https:\/\/doi.org\/10.2147\/OTT.S168317","journal-title":"OncoTargets Ther"},{"key":"12607_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529847","volume":"16","author":"F Verona","year":"2025","unstructured":"Verona F, Di Bella S, Schirano R et al (2025) Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction. Front Immunol 16:1529847. https:\/\/doi.org\/10.3389\/fimmu.2025.1529847","journal-title":"Front Immunol"},{"key":"12607_CR91","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells9030561","volume":"9","author":"AMK Law","year":"2020","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D (2020) Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells 9:561. https:\/\/doi.org\/10.3390\/cells9030561","journal-title":"Cells"},{"key":"12607_CR92","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B et al (2021) Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 6:362. https:\/\/doi.org\/10.1038\/s41392-021-00670-9","journal-title":"Signal Transduct Target Ther"},{"key":"12607_CR93","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R et al (2024) Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA 331:1135. https:\/\/doi.org\/10.1001\/jama.2024.3056","journal-title":"JAMA"},{"key":"12607_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104120","volume":"10","author":"I Schlam","year":"2025","unstructured":"Schlam I, Loi S, Salgado R, Swain SM (2025) Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges. ESMO Open 10:104120. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104120","journal-title":"ESMO Open"},{"key":"12607_CR95","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"12607_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00411","author":"S Ville","year":"2015","unstructured":"Ville S, Poirier N, Blancho G, Vanhove B (2015) Co-stimulatory blockade of the CD28\/CD80\u201386\/CTLA-4 balance in transplantation: impact on memory T cells? Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00411","journal-title":"Front Immunol"},{"key":"12607_CR97","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/cncr.34084","volume":"128","author":"RR Malla","year":"2022","unstructured":"Malla RR, Vasudevaraju P, Vempati RK, Rakshmitha M, Merchant N, Nagaraju GP (2022) Regulatory T cells: their role in triple\u2010negative breast cancer progression and metastasis. Cancer 128:1171\u20131183. https:\/\/doi.org\/10.1002\/cncr.34084","journal-title":"Cancer"},{"key":"12607_CR98","doi-asserted-by":"publisher","first-page":"1507283","DOI":"10.3389\/fimmu.2024.1507283","volume":"15","author":"H Xie","year":"2024","unstructured":"Xie H, Xi X, Lei T, Liu H, Xia Z (2024) CD8+ T cell exhaustion in the tumor microenvironment of breast cancer. Front Immunol 15:1507283. https:\/\/doi.org\/10.3389\/fimmu.2024.1507283","journal-title":"Front Immunol"},{"key":"12607_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112808","volume":"28","author":"RH Mebane","year":"2025","unstructured":"Mebane RH, Noel T, Ing N et al (2025) Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures. iScience 28:112808. https:\/\/doi.org\/10.1016\/j.isci.2025.112808","journal-title":"iScience"},{"key":"12607_CR100","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13058-025-02183-7","volume":"28","author":"J Pantaleo","year":"2026","unstructured":"Pantaleo J, Sj\u00f6lund J, Bolivar P et al (2026) Spatial and temporal dynamics of cancer-associated fibroblast niches in breast cancer. Breast Cancer Res 28:21. https:\/\/doi.org\/10.1186\/s13058-025-02183-7","journal-title":"Breast Cancer Res"},{"key":"12607_CR101","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2026.04.023","volume":"189","author":"ED Shulman","year":"2026","unstructured":"Shulman ED, Campagnolo EM, Lodha R et al (2026) AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology. Cell 189:4225-4240.e25. https:\/\/doi.org\/10.1016\/j.cell.2026.04.023","journal-title":"Cell"},{"key":"12607_CR102","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387:217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"key":"12607_CR103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-024-07555-9","volume":"209","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Campbell M, Yau C et al (2025) Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat 209:487\u2013492. https:\/\/doi.org\/10.1007\/s10549-024-07555-9","journal-title":"Breast Cancer Res Treat"},{"key":"12607_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000664","volume":"8","author":"BC Cho","year":"2020","unstructured":"Cho BC, Daste A, Ravaud A et al (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer 8:e000664. https:\/\/doi.org\/10.1136\/jitc-2020-000664","journal-title":"J Immunother Cancer"},{"key":"12607_CR105","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K (2023) Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med 55:2308\u20132319. https:\/\/doi.org\/10.1038\/s12276-023-01114-w","journal-title":"Exp Mol Med"},{"key":"12607_CR106","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko JH, Hollm\u00e9n M (2024) Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br J Cancer 131:627\u2013640. https:\/\/doi.org\/10.1038\/s41416-024-02715-6","journal-title":"Br J Cancer"},{"key":"12607_CR107","doi-asserted-by":"publisher","first-page":"2500296","DOI":"10.1002\/advs.202500296","volume":"12","author":"L Gehrcken","year":"2025","unstructured":"Gehrcken L, Deben C, Smits E, Van Audenaerde JRM (2025) STING agonists and how to reach their full potential in cancer immunotherapy. Adv Sci 12:2500296. https:\/\/doi.org\/10.1002\/advs.202500296","journal-title":"Adv Sci"},{"key":"12607_CR108","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"F-C Bidard","year":"2025","unstructured":"Bidard F-C, Mayer EL, Park YH et al (2025) First-line Camizestrant for emerging ESR1 -mutated advanced breast cancer. N Engl J Med 393:569\u2013580. https:\/\/doi.org\/10.1056\/NEJMoa2502929","journal-title":"N Engl J Med"},{"key":"12607_CR109","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Venet D, Lifrange F et al (2024) Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun 15:10232. https:\/\/doi.org\/10.1038\/s41467-024-54145-w","journal-title":"Nat Commun"},{"key":"12607_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02426-3","volume":"24","author":"J Le","year":"2025","unstructured":"Le J, Dian Y, Zhao D et al (2025) Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment. Mol Cancer 24:221. https:\/\/doi.org\/10.1186\/s12943-025-02426-3","journal-title":"Mol Cancer"},{"key":"12607_CR111","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","volume":"30","author":"J Klughammer","year":"2024","unstructured":"Klughammer J, Abravanel DL, Segerstolpe \u00c5 et al (2024) A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nat Med 30:3236\u20133249. https:\/\/doi.org\/10.1038\/s41591-024-03215-z","journal-title":"Nat Med"},{"key":"12607_CR112","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ccell.2023.06.009","volume":"41","author":"Y Li","year":"2023","unstructured":"Li Y, Dou Y, Da Veiga LF et al (2023) Proteogenomic data and resources for pan-cancer analysis. Cancer Cell 41:1397\u20131406. https:\/\/doi.org\/10.1016\/j.ccell.2023.06.009","journal-title":"Cancer Cell"},{"key":"12607_CR113","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","volume":"10","author":"F Panet","year":"2024","unstructured":"Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M (2024) Use of ctDNA in early breast cancer: analytical validity and clinical potential. Npj Breast Cancer 10:50. https:\/\/doi.org\/10.1038\/s41523-024-00653-3","journal-title":"Npj Breast Cancer"},{"key":"12607_CR114","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1200\/JCO.21.02285","volume":"40","author":"BP Hobbs","year":"2022","unstructured":"Hobbs BP, Pestana RC, Zabor EC, Kaizer AM, Hong DS (2022) Basket trials: review of current practice and innovations for future trials. J Clin Oncol 40:3520\u20133528. https:\/\/doi.org\/10.1200\/JCO.21.02285","journal-title":"J Clin Oncol"},{"key":"12607_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"X-P Duan","year":"2024","unstructured":"Duan X-P, Qin B-D, Jiao X-D, Liu K, Wang Z, Zang Y-S (2024) New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Ther 9:57. https:\/\/doi.org\/10.1038\/s41392-024-01760-0","journal-title":"Signal Transduct Target Ther"},{"key":"12607_CR116","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41586-025-10004-2","volume":"651","author":"U Sahin","year":"2026","unstructured":"Sahin U, Schmidt M, Derhovanessian E et al (2026) Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature 651:1088\u20131096. https:\/\/doi.org\/10.1038\/s41586-025-10004-2","journal-title":"Nature"},{"key":"12607_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1890594","volume":"17","author":"AA Mathew","year":"2026","unstructured":"Mathew AA, Rithvik A, Rasool M (2026) Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs. Front Immunol 17:1890594. https:\/\/doi.org\/10.3389\/fimmu.2026.1890594","journal-title":"Front Immunol"},{"key":"12607_CR118","doi-asserted-by":"publisher","DOI":"10.1007\/s13237-025-00618-2","author":"AA Mathew","year":"2025","unstructured":"Mathew AA, Raheja R, Raj AS (2025) CAR T cells beyond cancer: emerging applications in autoimmunity and infectious diseases. Nucleus. https:\/\/doi.org\/10.1007\/s13237-025-00618-2","journal-title":"Nucleus"},{"key":"12607_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105082","volume":"218","author":"D Stylianakis","year":"2026","unstructured":"Stylianakis D, Benjamin HA, Martella S et al (2026) Spatial multiomics of the breast tumour microenvironment: state of the field, advancements and clinical implementation promises. Crit Rev Oncol Hematol 218:105082. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105082","journal-title":"Crit Rev Oncol Hematol"},{"key":"12607_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152435","volume":"17","author":"T Graf","year":"2025","unstructured":"Graf T, Boos LA, Mehra T et al (2025) Precision oncology guided by genomic profiling in breast cancer: real-world data from a molecular tumor board. Cancers (Basel) 17:2435. https:\/\/doi.org\/10.3390\/cancers17152435","journal-title":"Cancers (Basel)"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12607-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12607-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12607-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:40:46Z","timestamp":1787654446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12607-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12607"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12607-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its publication.","order":3,"name":"Ethics","label":"Written consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1457"}}